

Sub C5
B1
CON 4
21(Once-amended). Transformed cells having the nucleotide sequence according to claim 2 in an expressible state.

22(Once-amended). A process for producing a protein which comprises culturing cells transformed with the nucleotide sequence according to claim 2, and collecting hBSSP6 produced.

B2
25(Once-amended). The process according to claim 22, wherein the cells are *E. coli* cells, animal cells or insect cells.

B3
30(Once-amended). An antibody against the protein according to claim 1 or a fragment thereof.

Sub 7
32(Once-amended). A process for producing a monoclonal antibody against the protein according claim 1 or a fragment thereof which comprises administering the protein according to claim 1 or a fragment thereof to a warm-blooded animal other than a human being, selecting the animal whose antibody titer is recognized, collecting its spleen or lymph node, fusing the antibody producing cells contained therein with myeloma cells to prepare a monoclonal antibody producing hybridoma.

B4
33(Once-amended). A method for determining the protein according to claim 1 or a fragment thereof in a specimen which is based on immunological binding of an antibody against the protein or a fragment thereof to the protein or a fragment thereof.

34(Once-amended). A method for determining BSSP6 or a fragment thereof in a specimen which comprises reacting a

35(Once-amended). A method for determining BSSP6 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein according to claim 1 or a fragment thereof with labeled BSSP6 and BSSP6 or a fragment thereof in the specimen competitively to detect an amount of BSSP6 or a fragment thereof in the specimen based on an amount of the labeled BSSP6 reacted with the antibody.

36(Once-amended). The method according to claim 33,
wherein the specimen is a body fluid.

37 (Once-amended). A diagnostic marker for diseases in tissues comprising the protein according to claim 1, or a fragment thereof.

41(Once-amended). The marker according to claim 27
37 to be used for diagnosis of prostatic hypertrophy in
prostate.